InvestorsHub Logo
Post# of 251721
Next 10
Followers 92
Posts 17190
Boards Moderated 0
Alias Born 09/06/2006

Re: investorgold2002 post# 120714

Monday, 05/30/2011 5:54:15 PM

Monday, May 30, 2011 5:54:15 PM

Post# of 251721

why are they saying the proposed generic's avg mol weight or peak mol weight does not conform to within claimed ranges of branded drug copaxone ?



The patent's range of average MW is 4-8.6 kD. The FDA label states 4.7-11 kD.

Is the 4-8.6 range better? I neither know nor care. Copaxone is defined by what the FDA says it is. If TEVA had wished to submit some data stating that lower weight was better and get that approved, fine. But they did not. Instead they told the FDA they higher weight was fine,

If all they did was tweek the range a tad in order to gain a new patent, that is obvious.

Try looking at it this way. Does Copaxone infringe on the '847 patent? If yes, then you would have to explain how a third party could have come up with the same '847 patent a decade after Copaxone was on the market and claim infringement. If no, then a clone of Copaxone will not infringe. If you believe Copaxone was improved, then you need to ask why it no longer conforms to the FDA label.

I seriously doubt the CoM patents will both hold up and be deemed reading. One or the other, but not both.

The process patents are right up MNTA's alley, they will be able to non-infringe very easy, unless MNTA is a scam, in which case I will have to kill DD smile

On a lighter side, I believe the Indian courts have already rulled the patents invalid smile

P.S., agree that this really matters little. It's the FDA, stupid.




Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.